VTX 1463

Drug Profile

VTX 1463

Alternative Names: VTX-1463

Latest Information Update: 15 Feb 2017

Price : $50

At a glance

  • Originator Array BioPharma
  • Developer VentiRx Pharmaceuticals
  • Class Antiallergics; Small molecules
  • Mechanism of Action Toll-like receptor 8 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Allergic rhinitis

Most Recent Events

  • 14 Feb 2017 VentiRx Pharmaceuticals has been acquired by Celgene Corporation
  • 05 Apr 2016 Phase I development is ongoing in Austria & the Netherlands
  • 21 Mar 2011 Efficacy and safety data from a phase-I trial in Allergic rhinitis presented at the 67th Annual Meeting of the American Academy of Allergy, Asthma and Immunology (AAAAI-2011)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top